Bionexus Gene Lab CORP

BioNexus Gene Lab Corp. announces progress in commercializing its VitaGuard MRD platform in Southeast Asia following a working visit to China, with initial deployments targeted for 2026.

BioNexus Gene Lab Corp. highlighted its strategic vision for cross-border biotechnology co-development at the 2026 China-Malaysia Economic Cooperation Outlook Forum.

BioNexus Gene Lab Corp. announced the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to lead global commercialization efforts for its VitaGuard MRD platform.

BioNexus Gene Lab Corp. announced a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., streamlining its board and appointing Matthew L. Barsing as Chairman.

BioNexus Gene Lab Corp. announced the formal commencement of its 2026 regional deployment phase for the VitaGuard Minimal Residual Disease (MRD) platform in Southeast Asia.

BioNexus Gene Lab Corp. stockholders approved the election of directors, a 2025 Equity Incentive Plan, and the independent auditor at their Annual Meeting.

BioNexus Gene Lab Corp. reports a significant revenue decline for Q1 2026 amid internal control remediation and legal action against former management.

BioNexus Gene Lab Corp. reports a wider net loss for the nine months ended September 30, 2025, while pursuing strategic shifts into biotech CDMO and digital asset treasury.

BioNexus Gene Lab Corp. reported a significant net loss for the six months ended June 30, 2025, as it pivots towards biotechnology CDMO, expands genomic screening, and adopts an Ethereum treasury strategy.

BioNexus Gene Lab Corp. announces its Q1 2025 financial results, highlighting a strategic shift towards digital assets and addressing Nasdaq compliance while experiencing a revenue decrease.

BioNexus Gene Lab Corp. reports a net loss for Q3 2024, alongside ongoing internal investigations and a Nasdaq delisting notice.

BioNexus Gene Lab Corp. saw a decrease in revenue but an increase in profitability for the second quarter of 2024, compared to the same period last year.

Bionexus Gene Lab Corp. filed its annual report for the fiscal year ended December 31, 2025, detailing revenue decline, strategic partnerships, and ongoing governance remediation.

BioNexus Gene Lab Corp. files an amendment to its 2024 annual report to include its policy on recovery of erroneously awarded compensation (clawback policy) to comply with SEC and Nasdaq regulations.

BioNexus Gene Lab Corp. announces its fiscal year 2024 results, highlighting a strong liquidity position, strategic innovation initiatives, and proactive governance enhancements while addressing Nasdaq compliance challenges.

BioNexus Gene Lab Corp. has filed an amendment to its annual report to address comments from the SEC regarding the effectiveness of its disclosure controls and procedures.

Bionexus Gene Lab Corp. has filed an amendment to its 2022 annual report to correct inaccuracies regarding its internal controls and procedures, following a comment letter from the SEC.

BioNexus Gene Lab Corp. reports a decrease in revenue and a net loss for 2023, alongside significant changes in management and strategic direction.

BioNexus Gene Lab Corp. announces its 2025 Annual Meeting of Stockholders to vote on director re-elections, a new equity incentive plan, and auditor re-appointment.

BioNexus Gene Lab Corp. is holding a special meeting to seek stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and gain flexibility for future capital raising.

BioNexus Gene Lab Corp. is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and gain flexibility for future capital raising.

BioNexus Gene Lab Corp. is holding its annual meeting on October 4, 2024, to vote on key proposals including the election of directors, a reverse stock split, and a new stock incentive plan.

BioNexus Gene Lab Corp. announces the removal of eight directors and the election of three new directors via written consent from stockholders holding approximately 50.1% of voting securities.